Literature DB >> 7092915

Hypothermia as a mechanism for drug-induced resistance to hypoxia.

F N Minard, D S Grant.   

Abstract

A linear regression line relating the logarithm of survival time in a standard hypoxia survival test (4.6% oxygen) with hypothermia was obtained upon cooling mice by exposure to either a graded hypoxia or a cold environment. When S/BT values (log minutes survival versus body temperature) of drug-treated animals were compared with this regression line, values for many drugs lay on the line, indicating that their effects upon hypoxic survival were no greater than those expected from the concomitant hypothermia. Among the drugs whose anti-hypoxia effects were explained by their production of hypothermia were adenosine, diazepam, diphenylhydantoin, pentobarbital and physostigmine. The anti-hypoxia activity of each drug had been reported previously by other investigators and ascribed to numerous mechanisms. The present observations relating hypothermia with increased survival in hypoxia provide a rationale for the protective effect of the above drugs in animals suddenly exposed to lethal hypoxia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7092915     DOI: 10.1016/0006-2952(82)90004-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

Review 1.  The therapeutic potential of regulated hypothermia.

Authors:  C J Gordon
Journal:  Emerg Med J       Date:  2001-03       Impact factor: 2.740

2.  Moderate hypoxia does not affect the zone of thermal comfort in humans.

Authors:  P Golja; A Kacin; M J Tipton; I B Mekjavic
Journal:  Eur J Appl Physiol       Date:  2005-01-22       Impact factor: 3.078

3.  Positive feedback between oncogenic KRAS and HIF-1α confers drug resistance in colorectal cancer.

Authors:  Yanzhao Wang; Fuming Lei; Wanshui Rong; Qingmin Zeng; Wenbing Sun
Journal:  Onco Targets Ther       Date:  2015-05-26       Impact factor: 4.147

4.  High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer.

Authors:  Takuya Shiraishi; Koji Ikeda; Yuichiro Tsukada; Yuji Nishizawa; Takeshi Sasaki; Masaaki Ito; Motohiro Kojima; Genichiro Ishii; Ryo Tsumura; Sinji Saijou; Yoshikatsu Koga; Masahiro Yasunaga; Yasuhiro Matsumura
Journal:  BMC Cancer       Date:  2021-03-23       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.